Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | DUSP1 | P28562 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865105 | 0.91 | RAB9A (0.69) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL27690747 | 0.91 | GAA (0.79) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL2862550 | 0.86 | RAB9A (0.62) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL4362238 | 0.86 | RAB9A (0.62) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL3145150 | 0.85 | KMT2A (0.56) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL4366508 | 0.81 | KMT2A (0.60) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL2866086 | 0.81 | GAA (0.65) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL2865869 | 0.81 | KMT2A (0.65) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL2862776 | 0.80 | KMT2A (0.55) | RAB9AKMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL27690771 | 0.80 | KDM4E (0.53) | RAB9AKMT2AKDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | claimed |
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | claimed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | claimed |
| CN-101087755-A | Substituted arylacylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC (US) | 2007-12-12 | — | — | CN | claimed |
| EP-1747196-A2 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2006083271-A2 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | claimed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | disclosed |
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | PIGS, NAT1, AADAC | RAB9A 2277/4885KMT2A 1501/4885KDM4E 1736/4885 |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | RAB9A 3144/4885KMT2A 4579/4885KDM4E 3665/4885 |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | PIGS, NAT1, AADAC | RAB9A 2277/4885KMT2A 1501/4885KDM4E 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.